Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ertapenem + metronidazole
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
A combination antibiotic therapy consisting of ertapenem (a carbapenem antibiotic) and metronidazole (an antibiotic effective against anaerobic bacteria). This combination is used primarily for complicated intra-abdominal infections (cIAIs). While ertapenem alone has broad-spectrum activity that covers many aerobic and anaerobic bacteria, it may be combined with metronidazole in certain clinical scenarios for enhanced anaerobic coverage or based on institutional protocols.
02
Targets
PBP2 (Penicillin-binding protein 2)Neuraminidase
Beyond the preview
Go deeper on ertapenem + metronidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ertapenem + metronidazole.